ABSK021 for untreated advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new drug called ABSK021 for people with advanced pancreatic cancer who have not received any prior treatment. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your pancreatic cancer is advanced and cannot be removed by surgery, or has spread to other parts of the body.
- You have not had any prior chemotherapy or other systemic treatment for your pancreatic cancer.
- You are able to perform daily activities with mild or no help (ECOG score 0-2).
- You have no serious infections, heart problems, or other cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (MRG004A) for advanced pancreatic cancer that has not responded to earlier treatments. The drug is given together with best supportive care (treatments to manage symptoms), and compared to a placebo (a dummy treatment) with best supportive care. The goal is to see if the new drug can slow down the cancer and help you live longer.
This study tests a new treatment for people with stage 4 pancreatic cancer who haven't yet had any treatment for advanced disease. The goal is to see if the new treatment can help shrink or control the cancer.
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This study tests a combination of three drugs—two pills and one infusion—for people with advanced pancreatic cancer who have already tried one or more treatments. It may help shrink tumors or slow the cancer's growth.
This trial tests three new targeted drug combinations for pancreatic cancer that has a specific genetic change (KRAS G12D). They are comparing the study drug alone versus combining it with other investigational drugs to see which works better.
Hear when a new Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.